Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease

American Journal of Cardiology

Volumn 81, Issue 7, 1998, Pages 912-917

  Fruchart, Jean Charles ^a,d   Brewer Jr , H Bryan ^b   Leitersdorf, Eran ^c   Assmann, Gerd ^e   Brochier, Mireille ^e   Brown, Gregg ^e   Calvo, Carlos ^e   Carmena, Rafael ^e   Ceska, Richard ^e   Loy Soong, William Chew ^e   Davignon, Jean ^e   Gotto, Antonio ^e   Grundy, Scott ^e   Hamsten, Anders ^e   Keech, Anthony ^e   Matsuzawa, Yuji ^e   Patch, Josef R ^e   Paoletti, Rodolfo ^e   Raslova, Katarina ^e   Smirnov, Vladimir ^e   Steiner, George ^e   Thompson, Gilbert ^e   Zhu, Jun Ren ^e   more..

^a INSTITUT PASTEUR DE LILLE   (France)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d INSERM   (France)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; CLOFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR;

CLINICAL TRIAL; CORONARY RISK; DRUG EFFICACY; DRUG MECHANISM; DYSLIPOPROTEINEMIA; EDITORIAL; HUMAN; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL;

ANIMALS; ANTILIPEMIC AGENTS; CHOLESTEROL, LDL; CLOFIBRATE; CORONARY DISEASE; FEMALE; GEMFIBROZIL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIAS; MALE; RISK FACTORS;

EID: 0032054839     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00010-1     Document Type: Editorial

References (100)

1. 1. Scandinav Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
2. 2. Shepherd J. The West of Scotland Coronary Prevention Study: A trial of cholesterol reduction of Scottish men. Am J Cardiol 1995;76:113C-117C.
3. 3. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun C-C, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-1009.
4. 4. Grundy SM. National cholesterol education program: second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Circulation 1994;89:1329-1445.
5. 5. Prevention of coronary heart disease: scientific background and new clinical guidelines. Recommendations of the European Atherosclerosis Society prepared by intenational task force for prevention of coronary heart disease. Nut Metab Cardiovasc Dis 1992;2:113-156.
6. 6. Austin MA Hokanson JE. Epidemiology of triglycerides, small dense low-density lipoprotein, and lipoprotein(a) as risk factors for coronary heart disease. Med Clin North Am 1994;78:99-115.
7. 7. Brunzell JD. Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill, 1995:1913-1932.
8. 8. Benlian P, De Gennes JL, Foubert L, Zhang H, Gagne SE, Hayden M. Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene. N Engl J Med 1996;335:848-854.
9. 9. Brunzell JD, Schrott HG, Motulsky AG, Bierman EL. Myocardial infarction in the familial forms of hypertriglyceridemia. Metabolism 1976;25:313-320.
10. 10. Havel RJ. Postprandial hyperlipidemia and remnant lipoproteins. Curr Opin Lipidol 1994;5:102-109.
11. 11. Davignon J Cohn JS. Triglycerides: a risk factor for coronary heart disease. Atherosclerosis 1996;124:S57-S64.
12. 12. Superko HR. Beyond LDL cholesterol reduction. Circulation 1996;94:2351-2354.
13. 13. Grundy SM. Small LDL, atherogenic dyslipidemia and the metabolic syndrome. Circulation 1997;95:1-4.
14. 14. Schaefer EJ, Gregg RE, Ghiselli G, Forte TM, Ordovas JM, Zech LA, Brewer HB, Jr. Familial apolipoprotein E deficiency. J Clin Invest 1986;78:1206-1219.
15. 15. Mahley RW Rall SC Jr. Type II hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Stanbury JB, Wyngaarden JB, Fredrickson DS, eds. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill, 1995:1953-1980.
16. 16. Hegele RA, Little JA, Vezina C, Maguire GF, Tu L, Wolever TS, Jenkins DJA, Connelly PW. Hepatic lipase deficiency: clinical, biochemical, and molecular genetic characteristics. Arterioscler Thromb 1993;13:720-728.
17. 17. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart diseas. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 1973;52:1544-1568.
18. 18. Genest JJ Jr, Martin-Munley SS, McNamara JR, Ordovas JM, Jenner J, Myers RH, Silberman SR, Wilson PWF, Salem DN, Schaefer EJ. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992; 85:2025-2033.
19. 19. Austin MA. Plasma triglyceride and coronary heart disease. Arteriosclerosis 1991;11:2-14.
20. 20. Hokanson JE Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population based prospective studies. J Cardiovasc Risk 1996;3:213-219.
21. 21. Assmann G Schulte H. Role of triglycerides in coronary artery disease: lessons from the prospective cardiovascular munster study. Am J Cardiol 1992; 70:10H-13H.
22. 22. Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotien(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 1996;77:1179-1184.
23. 23. Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM, Hennekens CH. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996;276:882-888.
24. 24. Castelli WP. Epidemiology of triglycerides: a view from Framingham. Am J Cardiol 1992;70:3H-9H.
25. 25. Fontbonne A, Eschwege E, Cambien F, Richard JL, Ducimetiere P, Thibult N, Warnet JM, Claude JR, Rosselin GE. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 1989;32:300-304.
26. 26. Simpson HS, Williamson CM, Olivecrona T, Pringle S, Maclean J, Lorimer AR, Bonnefous F, Bogaievsky Y, Packard CJ, Shepherd J. Postprandial lipemia, fenofibrate and coronary artery disease. Atherosclerosis 1990;85:193-202.
27. 27. Patsch JR, Miesenböck G, Hopferwieser T, Mühlberger V, Knapp E, Dunn JK, Gotto AM Jr, Patsch W. Relation of triglyceride metabolism and coronary artery disease: studies in the postprandial state. Arterioscler Thromb 1992;12: 1336-1345.
28. 28. Cohn JS. Postprandial lipid metabolism. Curr Opin Lipidol 1994;5:185.
29. 29. Blankenhorn DH, Azen SP, Kramsch DM, Mack WJ, Cashin-Hemphill L, Hodis HN, DeBoer LW, Mahrer PR, Masteller MJ, Vailas LI, Alaupovic P, Hirsch LJ, and the MARS Research Group. Coronary angiographic changes with lovastatin therapy: the monitored atherosclerosis regression study (MARS). Ann Intern Med 1993;119:969-976.
30. 30. Alaupovic P, Mack WJ, Knight-Gibson C, Hodis HN. The role of triglyceride-rich lipoprotein families in the progress of atherosclerotic lesions are determine dby sequential coronary angiography from a controlled clinical trial. Arterioscler Thromb Vasc Biol 1997;17:715-722.
31. 31. Hodis HN, Mack WJ. Trigylceride-rich lipoproteins and the progression of coronary artery disease. Curr Opin Lipidol 1995;6:209-214.
32. 32. Mack WJ, Hodis HN. Efficacy of interventions designed to inhibit the progression of coronary atherosclerosis. Diabetes Res Clin Pract 1996;30:S37-S53.
33. 33. Hodis HN, Mack WJ, Azen SP, Alaupovic P, Pogoda JM, LaBree L, Hemphill LC, Kramsch DM, Blankenhorn DH. Triglyceride-and cholesterol-rich lipoproteins have differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 1994;90:42-49.
34. 34. Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996;347:849-853.
35. 35. Luc G, Fievet C, Arveiler D, Evans AE, Bard JM, Cambien F, Fruchart JC, Ducimetiere P. Apolipoprotein C-III and E in apoB-and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. J Lipid Res 1996;37:508-517.
36. 36. Ernst E Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993;118:956-963.
37. 37. ECTA Angia Pectoris Study Group. ECAT angina pectoris study: baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J 1993;14:8-17.
38. 38. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995;332:635-641.
39. 39. Meade TW, Mellow S, Brogovic M. Haemostatic function and ischemic heart disease: principal results of the Northrisk Park Heart Sudy. Lancet 1986;2:533-537.
40. 40. Davignon J. Fibrates: a review of important issues and recent findings. Can J Cardiol 1994;10:61B-71B.
41. 41. Sirtori CR Franceschini G. Effects of fibrates on serum lipids and atherosclerosis. Pharmacol Ther 1988;37:167-191.
42. 42. Erkelens DW, Chen C, Mitchell CD, Glomset JA. Studies of the interaction between apolipoproteins A and C and triacylglycerol-rich particles. Biochem Biophys Acta 1981;665:221-233.
43. 43. Fruchart JC, Davignon J, Bard JM, Grothe AM, Richard A, Fievet C. Effect of fenofibrate treatment on type III hyperlipoproteinemia. Am J Med 1987;83: 71-74.
44. 44. Schoonjans K, Staels B, Deeb S, Auwerx J. Fibrates and fatty acids induce lipoprotein lipase gene expression via the peroxisome proliferator activated receptors. Circulation 1995;92/8(SUPPL I):I-495.
45. 45. Staels B, Vu-Dac N, Kosykh V, Saladin R, Fruchart JC, Dallongeville J, Auwerx J. Fibrates down-regulate apolipoprotein CIII expression independent of induction of peroximsomal acyl co-enzyme A oxidase. J Clin Invest 1995;95: 705-712.
46. 46. Schoonjans K, Staels B, Auwex J. Role of the peroxisome proliferator-activated receptor (PRAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 1996;37:907-925.
47. 47. McConathy WJ, Gesquiere JC, Bass H, Tartar A, Fruchart J-C, Wang C-S. Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III. J Lipid Res 1992;33:995-1003.
48. 48. Heller F Harvengt C. Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects. Eur J Clin Pharmacol 1983;25:57-63.
49. 49. Goldberg AP, Applebaum-Bowden DM, Bierman EL, Hazzard WR, Haas LB, Sherrard DJ, Brunzell JD, Huttunen JK, Ehnholm C, Nikkilä EA. Increase in lipoprotein lipase during clofibrate treatment of hypertriglyceridemia in patients on hemodialysis. N Engl J Med 1979;301:1073-1076.
50. 50. Haubenwallner IS, Essenburg AD, Barnett BC, Pape ME, DeMattos RB, Krause BR, Minton LL, Auerbach BJ, Newton RS, Leff T. Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein CIII expression: a potential physiologic basis for their mode of action. J Lipid Res 1995;36:2541-2551.
51. 51. Hertz JR, Bishara-Shieban J, Bar-Tana J. Mode of action of peroxisome proliferators as hypolipidemic drugs. Suppression of apolipoprotein C-III. J Biol Chem 1995;270:13470-13475.
52. 52. Schoonjans K, Watanabe M, Suzuki H, Mahfoudi A, Krey G, Wahli W, Grimaldi P, Staels B, Yamamoto T, Auwerx J. Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promotor. J Biol Chem 1995;70:19269-19276.
53. 53. Schoonjans K, Staels B, Grimaldi P, Auwerx J. Acyl-CoA synthetase mRNA expression is controlled by fibric-acid derivatives, feeding and liver proliferation. Eur J Biochem 1993;216:615-622.
54. 54. Lamb RG, Koch JC, Bush SR. An enzymatic explanation of the differential effects of oleate and gemfibrozil on cultured hepatocyte tracylglycerol and phosphatidylcholine biosynthesis and secretion. Biochim Biophys Acta 1993; 1165:299-305.
55. 55. Nigon F, Lesnik P, Rouis M, Chapman MJ. Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor. J Lipid Res 1991;32:1741-1753.
56. 56. Caslake MJ, Packard CJ, Gaw E, Murray E, Griffin BA, Vallance BD, Shepherd J. Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia. Arterioscler Thromb 1993;13:702-711.
57. 57. Mann CJ, Yen FT, Grant AM, Bihain BE. Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia. J Clin Invest 1991;88:2059-2066.
58. 58. Vu-Dac N, Schoonjans K, Kosykh V, Dallongeville J, Fruchart JC, Staels B, Auwerx J. Fibrates increase haman apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest 1995;96: 741-750.
59. 59. Berthou L, Staels B, Saldicco I, Berthelot K, Casey J, Fruchart JC, Denefle P, Branellec D. Opposite in vitro and in vivo regulation of hepatic apolipoprotein A-I gene expression by retinoic acid: absence of effects on apolipoprotein A-II gene expression. Arterioscler Thromb 1994;14:1657-1664.
60. 60. European Atherosclersosis Society. The recognition and management of hyperlipidemia in adults: a policy statement of the European Atherosclerosis Society. Eur Heart J 1988;9:571-660.
61. 61. Bradford RH, Goldberg AC, Schonfeld G, Knopp RH. Double-bind comparison of bezafibrate versus placebo in male volunteers with hyperlipoproteinemia. Atherosclerosis 1992;92:31-40.
62. 62. Pauciullo P, Marotta G, Rubba P, Cortese C, Caruso M, Cnasso A, Fischetti A, Motti C, Mancini M. Serum lipoproteins, apolipoproteins and very low density lipoprotein subfractions during 6-month fribrate treatment in primary hypertriglyceridaemia. J Intern Med 1990;228:425-430.
63. 63. Kleinman Y, Eisenberg S, Oschry Y, Gavish D, Stein O, Stein Y. Defective metabolism of hypertriglyceridemic low density lipoprotein in cultured human skin fibroblasts. Normalization with bezafibrate therapy. J Clin Invest 1985;75: 1796-1803.
64. 64. Bhatnagar D, Durrington PN, Mackness MI, Arrol S, Winocour PH, Prais H. Effects of treatment of hypertriglyceridemia with gemfibrozil on serum lipoproteins and the transfer of cholesteryl ester from high density lipoproteins to low density lipoproteins. Atherosclerosis 1992;92:49-57.
65. 65. Simo IE, Yakichuk JA, Ooi TC. Effect of gemfibrozil and lovastatin on postprandial lipoprotein clearance in the hypoalphalipoproteinemia and hypertriglyceridemia syndrome. Atherosclerosis 1993;100:55-64.
66. 66. Ditschuneit HH, Fletchner-Mors M, Hagel E, Ditschuneit H. Postprandial lipoprotein metabolism in obses patients with moderate hypertriglyceridaemia: effect of gemfibrozil. J Intern Med Res 1992;20:197-210.
67. 67. Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation 1993;88:2762-2770.
68. 68. Karpe F, Steiner G, Uffelman K, Olivecrona T, Hamsten A. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis 1994; 106:83-97.
69. 69. Betteridge DJ. Ciprofibrate - a profile. Postgrad Med J 1993;69:S42-S47.
70. 70. Wolf HR. Efficacy and tolerability of etofibrate and gemfibrozil in combined hyperlipidaemia. Drug Exp Clin Res 1994;20:109-113.
71. 71. Cattin L, Da-Col PG, Feruglio FS, Finazzo L, Rimondi S, Descovich G, Manzato E, Zambon S, Crepaldi G, Siepi D. Efficacy of ciprofibrate in primary type II and IV hyperlipidemia: the Italian multicenter study. Clin Ther 1990;12: 482-488.
72. 72. Bruckert E, Dejager S, Chapman MJ. Ciprofibrate therapy normalizes the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia. Atherosclerosis 1993;100:91-102.
73. 73. Sirtori C, Franceschini G, Gianfranceschini G, Vaccarino V, Chiesa G, Maderna P, Bertoli M, Calabresi L. Activity profile of gemfibrozil on the major plasma lipoprotein parameters. Eur J Epidemiol 1992;8:120-124.
74. 74. Lupien PJ, Brun D, Gagne C, Moorjani S, Bielman P, Julien P. Gemfibrozil therapy in primary type II hyperlipoproteinemia: effects on lipids, lipoproteins and apolipoproteins. Can J Cardiol 1991;7:27-33.
75. 75. Tilly-Kiesi M Tikkanen MJ. Low density lipoprotein density and composition in hypercholesterolaemic men treated with HMG CoA reductase inhibitors and gemfibrozil. J Intern Med 1991;229:427-434.
76. 76. de Graaf J, Hendriks JCM, Demacker PNM, Stalenhoef AFH. Identification of multiple dense LDL subfractions with enhanced susceptibility to in vitro oxidation among hypertriglyceridemic subjects: normalization after clofibrate treatment. Arteriosclerosis and Thrombosis 1993;13:712-719.
77. 77. Zelis R, Mason DT, Braunwald E, Levy RI. Effects of hyperlipoproteinemias and their treatment on the peripheral circulation. J Clin Invest 1970;49:1007-1015.
78. 78. Syvanne CM, Vuorinen-Markkola H, Hilden H, Taskinen M-R. Gemfibrozil reduces postprandial lipemia in non-insulin-dependent diabetes mellitus. Arterioscler Thromb 1993;13:286-295.
79. 79. Belcaro G, Laurora G, Cesarone MR, De-Sanctis MT, Renton S, Veller M, Fisher C, Nicolaides AN. Non-invasive ultrasonic biopsy in the classification of early arterial lesions and in the evaluation of the rate of progression of arteriosclerosis. Panminerva Med 1992;34:107-114.
80. 80. Niort G, Cassader M, Gambiano R, Pagano G. Comparison of the effects of bezafibrate and acipimox on the lipid pattern and plasma fibrinogen in hyperlipidaemia type 2 (non-insulin-dependent) diabetic patients. Diabete Metab 1992; 18:221-228.
81. 81. Niort G, Gambino R, Cassader M, Pagano G. Bezafibrate affects lipid, lipoapolipoprotein pattern in non-insulin-dependent diabetic patients. Horm Metab Res 1993;25:372-374.
82. 82. Vinik AI Colwell JA. Effects of gemfibrozil on triglyceride levels in patients with NIDDM. Hyperlipidemia in diabetes investigators. Diabetes Care 1993;16:37-44.
83. 83. Sweany AE, Shapiro DR, Tate AC, Goldberg RB, Stein EA. Effects of simvastatin versus gemfibrozil on lipids and glucose control in patients with non-insulin-dependent diabetes mellitus. Clin Ther 1995;17:186-203.
84. 84. Stewart MW, Dyer RG, Alberti KG, Laker MF. The effects of lipid lowering drugs on metabolic control and lipoprotein composition in type 2 diabetic patients with mild hyperlipidaemia. Diabete Metab 1995;12:250-257.
85. 85. Goldberg R, La Belle P, Zupkis R, Ronca P. Comparison of the effects of lovastatin and gemfibrozil on lipids and glucose control in non-insulin-dependent diabetes mellitus. Am J Cardiol 1990;66:16B-21B.
86. 86. Beuers U, Ritter MM, Richter WO, Paumgartner G. Lipoprotein (a) serum levels in chronic cholestatic liver disease during treatment with ursodeoxycholic acid [letter]. Arch Intern Med 1990;150:1542.
87. 87. Acoltzin C Lezama Y. Lack of apolipoprotein A1 in patients recovering from myocardial infarction. Am J Cardiol 1990;66:124.
88. 88. Vuorinen-Markkola H, Yki-Järvinen H, Taskinen M-R. Lowering of triglycerides by gemfibrozil affects neither the glucoregulatory nor antilipolytic effect of insulin in Type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36:161-169.
89. 89. Winocour PH, Durrington PN, Bhatagnar D, Ishola M, Mackness M, Arrol S, Anderson DC. The effect of bezafibrate on very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), and low density lipoprotein (LDL) composition in type 1 diabetes associated with hypercholesterolaemia or combined hyperlipidaemia. Atherosclerosis 1992;93:83-94.
90. 90. Winocour PH, Durrington PN, Bhatnagar D, Ishola M, Arrol S, Lalor BC, Anderson DC. Double-blind placeblo-controlled study of the effects of bezafibrate on blood lipids, lipoproteins, and fibrinogen in hyperlipideaemic type 1 diabetes mellitus. Diabete Metab 1990;7:736-743.
91. 91. Shviro I, Leitersdorf E. Targeted prevention of coronary artery disease: pharmacological considerations in multiimodality treatment. Cardiology 1996; 87:469-475.
92. 92. Pierce R, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990;264:71-75.
93. 93. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 1978;40:1069-1118.
94. 94. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety in treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-1245.
95. 95. Hahmann HW, Bunte T, Hellwig N, Hau U, Becker D, Dyckmans J, Keller HE, Schieffer HJ. Progression and regression of minor arterial narrowings by quantitative angiography after fenofibrate therapy. Am J Cardiol 1991;67:957-961.
96. 96. Bunte T, Hahmann HW, Hellwig N, Hau U, Becker D, Dyckmans J, Keller HE, Schieffer HJ. Effects of fenofibrate on angiographically examined coronary atherosclerosis and left ventricular function in hypercholesterolemic patients. Atherosclerosis 1993;98:127-138.
97. 97. Frick MH, Syvanne M, Nieminen MS, Kauma H, Majahalme S, Virtanen V, Kesaniemi A, Pasternack A, Taskinen M-R. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Circulation 1997;96:2137-2143.
98. 98. Goldbourt U, Behar S, Reicher-Reiss H, Agmon J, Kaplinsky E, Graff E, Kishon Y, Caspi A, Weisbort J, Mandelzweig L, Abinader E, Aharon L, Braun S, David D, Flich M, Friedman Y, Kristal N, Leil N, Markiewicz W, Marmor A. Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the bezafibrate infarction prevention trial). Am J Cardiol 1993;71:909-915.
99. 99. Rubins HB, Robins SJ, Iwane MK, Boden WE, Elem MB, Fye CL, Gordon DJ, Schaefer EJ, Schectman G, Wittes JT. Rational and design of the Department of Veterans Affairs High Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol. Am J Cardiol 1993;71:45-52.
100. 100. Steiner G. The diabetes atherosclerosis intervention study (DAIS): a study conducted in cooperation with the World Health Organization. Diabetologia 1996;39:1655-1661.